The Hindu

Dr. Reddys forays into Indias biosimilar immuno-oncology market, launches Nivorz

In 2025, the immuno-oncology market in India was estimated to be around 3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.